Cash and Short Term Investments (Quarterly) Chart

View Cash and Short Term Investments (Quarterly) for IOVA.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View Cash and Short Term Investments (Quarterly) Chart
Start Trial

Historical Cash and Short Term Investments (Quarterly) Data

View and export this data back to 2008. Start Trial.
Date Value
June 30, 2026 297.67M
March 31, 2026 313.44M
December 31, 2025 296.98M
September 30, 2025 300.80M
June 30, 2025 301.18M
March 31, 2025 360.27M
December 31, 2024 323.78M
September 30, 2024 397.49M
June 30, 2024 412.62M
March 31, 2024 356.20M
December 31, 2023 279.87M
September 30, 2023 361.37M
June 30, 2023 250.89M
March 31, 2023 626.29M
December 31, 2022 471.84M
September 30, 2022 360.17M
June 30, 2022 424.46M
March 31, 2022 482.19M
December 31, 2021 504.41M
September 30, 2021 576.45M
June 30, 2021 656.37M
March 31, 2021 593.93M
December 31, 2020 629.44M
September 30, 2020 714.15M
June 30, 2020 771.88M
Date Value
March 31, 2020 245.65M
December 31, 2019 307.08M
September 30, 2019 361.87M
June 30, 2019 404.15M
March 31, 2019 440.02M
December 31, 2018 468.52M
September 30, 2018 260.00M
June 30, 2018 276.10M
March 31, 2018 297.08M
December 31, 2017 145.37M
September 30, 2017 163.38M
June 30, 2017 129.02M
March 31, 2017 147.20M
December 31, 2016 166.47M
September 30, 2016 179.28M
June 30, 2016 191.57M
March 31, 2016 99.17M
December 31, 2015 103.70M
September 30, 2015 110.15M
June 30, 2015 112.34M
March 31, 2015 111.28M
December 31, 2014 44.91M
September 30, 2014 17.19M
June 30, 2014 18.44M
March 31, 2014 17.94M

Cash and Short Term Investments Definition

Represents the sum of cash and short term investments.

Read full definition.

Cash and Short Term Investments (Quarterly) Range, Past 5 Years

View Cash and Short Term Investments (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Cash and Short Term Investments (Quarterly) Benchmarks

View Cash and Short Term Investments (Quarterly) Benchmarks
Start Trial
Amgen, Inc. 13.99B
Halozyme Therapeutics, Inc. 231.00M
Neurocrine Biosciences, Inc. 389.80M
AVITA Medical, Inc. 11.14M
Editas Medicine, Inc. 211.64M